Thus, not only ADAM12 and CYP1B1 can be seen as prognostic markers in RCC, but we also propose that interfering with the identified genes as well as hampering adiposity is an unmet adjuvant strategy in cancer therapy. This evidence concerns the gene CYP1B1 and cancer.